First of all, we will monitor the improvement in living standards and purchasing power around the world, on which a large part of Eli Lilly's business depends.

The growing awareness of health needs is also an element on which you can base your anticipations.

The ageing of the world's population is also an indicator to follow if you wish to take a position on this value.

We will also monitor the evolution of the market shares of generic drugs that are in direct competition with the drugs developed by Eli Lilly.

The global economic health will also influence the sales of this group.

Finally, we will of course also monitor the group's investments in R&D in the context of the development of new innovative treatments.

Pfizer 

This pharmaceutical company was founded in 1849 and operates in more than 150 countries. It is the world leader in its sector with a very large market capitalisation and turnover. Pfizer employs nearly 81,800 people worldwide.

Sanofi 

This French pharmaceutical group is active in several businesses including pharmaceuticals with products in the treatment of diabetes, rare diseases, multiple sclerosis, oncology, consumer and generic health products and vaccines.

Astrazeneca

The Astrazeneca group is also one of the leaders in this pharmaceutical sector in the world. It was created in 1999 following the merger of the Swedish company Astra and the British company Zeneca.

GlaxosmithKline or GSK 

This British multinational is also one of the giants of the pharmaceutical industry in the world. It was created from the merger of Glaxo Wellcome and SmithKline Beecham in 2000.

Bristol-Myers Squibb

This US pharmaceutical company has been in existence since 1989 and is the result of the merger of Bristol Myers Company and Squibb Corporation. Today and thanks to this merger, the group has become one of the largest in this sector.

Merck 

The Merck Group is a German company specialising in pharmaceuticals through Merck Serono, but also in chemicals.

Roche Holding 

This company is a Swiss pharmaceutical company and also one of the world's leading companies in this sector. It has been active since 2004 in two distinct sectors, including pharmaceuticals and diagnostics.

Dicerna Pharmaceuticals

First, Eli Lilly has signed a partnership with Dicerna Pharmaceuticals with a global licensing and research collaboration focused on the discovery, development and sale of potential new drugs for the treatment of cardiometabolic diseases, neurodegeneration or pain. The two companies plan to collaborate on the development of around ten drugs. The agreement provides for an upfront payment to Dicerna of $100 million and an equity investment of $100 million at a premium. Dicerna could also receive up to $350 million per target in development and commercialization stages.

AC Immune

Recently, Eli Lilly also signed a collaboration agreement with the Swiss company AC Immune to research and develop small molecule inhibitors of tau protein aggregation for the treatment of Alzheimer's disease and other such neurodegenerative disorders. This partnership will notably draw on AC Immune's technology platform, Morphomer, and Eli Lilly's expertise in clinical development and commercial capabilities. Initially, it will involve the molecule ACI-3024 with an initial payment of 80 million Swiss francs to AC Immune and $50 million in exchange for an option for an equity stake.